去纤苷使用量多少？

In October 2013, the European Commission granted marketing authorization under special circumstances to defibrotide sodium for the treatment of severe hepatic veno-occlusive disease in patients undergoing HSCT. It is the first and only approved treatment for severe hepatic veno-occlusive disease in Europe.

In Europe, defibrotide is indicated for patients older than one month. How much defibrotide should be used in patients who are allergic to defibrotide or any of its excipients or who are receiving concomitant thrombolytic therapy?

1. How to use defibrinoside:

The recommended dose of defibrotide for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol.

Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic veno-occlusive disease have not resolved after 21 days, continue defibrotide until resolution of hepatic veno-occlusive disease or until a maximum of 60 days.

2. Medication instructions:

Defibrotide must be diluted prior to infusion.

Before administration of defibrotide (alias: defibrotide sodium), confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.   

Defibrotide was administered by constant intravenous infusion over a 2-hour period.

Administer the diluted defibrotide solution using an infusion set equipped with a 0.2 μm in-line filter. Flush the intravenous administration line (peripheral or central) with 5% Glucose Injection, USP or 0.9% Sodium Chloride Injection, USP before and immediately after administration.

Do not coadminister with other intravenous medications at the same time and in the same intravenous line.

Related hot article recommendations:? /newsDetail/74943.html